Education
About Us
Working with TipRanks
Follow Us
Cellectis SA (CLLS)
NASDAQ:CLLS
CLLS Stock Chart & Stats
$3.58
-$0.20(-9.46%)
At close: 4:00 PM EST
$3.58
-$0.20(-9.46%)
Day’s Range― - ―
52-Week Range$1.10 - $5.48
Previous CloseN/A
Volume129.50K
Average Volume (3M)185.08K
Market Cap
$276.29M
Enterprise Value$68.67M
Total Cash (Recent Filing)$198.15M
Total Debt (Recent Filing)$113.83M
Price to Earnings (P/E)―
Beta2.94
Next Earnings
Nov 10, 2025EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding72,093,636
10 Day Avg. Volume212,821
30 Day Avg. Volume185,080
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.25
Enterprise Value/Revenue1.22
Enterprise Value/Gross Profit1.77
Enterprise Value/Ebitda-1.93
Forecast
1Y Price Target
$6.00Price Target Upside67.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessCellectis presented promising data from the Phase 1 BALLI-01 study with lasme-cel, showing a CR/CRi rate of 56% in heavily pretreated patients.
Manufacturing And Cost AdvantageLasme-cel is an anti-CD22 allogeneic CAR T cell therapy that is currently manufactured in-house by Cellectis, potentially offering cost advantages.
Research ProgressCellectis plans to report a data update with Eti-cel (UCART20x22) from the NATHALI-01 trial in r/r NHL, which may provide further insights into their research progress.
Bears Say
Commercial FeasibilityThere is uncertainty regarding the commercial feasibility of administering two rounds of CAR T and two rounds of HSCT with the suggested price for lasme-cel.
Enrollment ChallengesThere is uncertainty about the pace of enrollment in the pivotal Phase 2 trial for lasme-cel.
Potential Conflict Of InterestInvestors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report.
Cellectis SA News
CLLS FAQ
What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest stock price was $1.10 and its highest was $5.48 in the past 12 months.
What is Cellectis SA’s market cap?
Cellectis SA’s market cap is $276.29M.
When is Cellectis SA’s upcoming earnings report date?
Cellectis SA’s upcoming earnings report date is Nov 10, 2025 which is in 11 days.
How were Cellectis SA’s earnings last quarter?
Cellectis SA released its earnings results on Aug 04, 2025. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.214 by -$0.026.
Is Cellectis SA overvalued?
According to Wall Street analysts Cellectis SA’s price is currently Undervalued.
Does Cellectis SA pay dividends?
Cellectis SA does not currently pay dividends.
What is Cellectis SA’s EPS estimate?
Cellectis SA’s EPS estimate is -0.23.
How many shares outstanding does Cellectis SA have?
Cellectis SA has 72,093,636 shares outstanding.
What happened to Cellectis SA’s price movement after its last earnings report?
Cellectis SA reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.214. Following the earnings report the stock price went down -16.225%.
Which hedge fund is a major shareholder of Cellectis SA?
Among the largest hedge funds holding Cellectis SA’s share is Bpifrance SA. It holds Cellectis SA’s shares valued at 0.
Cellectis SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (67.60% Upside)
$6.00 (67.60% Upside)
Blogger Sentiment
Bullish
CLLS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.1%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
85.49%
12-Months-Change
Fundamentals
Return on Equity
-48.36%
Trailing 12-Months
Asset Growth
-13.06%
Trailing 12-Months
Company Description
Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
CLLS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive sentiment, driven by progress in clinical trials and strategic partnerships, despite financial and legal challenges. The successful advancement of pivotal trials and the strong collaboration with AstraZeneca are significant positives. However, the arbitration with Servier presents a notable uncertainty.View all CLLS earnings summariesCLLS Stock 12 Month Forecast
Average Price Target
$6.00
▲(67.60% Upside)
Technical Analysis
Cartesian Therapeutics
―
Foghorn Therapeutics
―
Vor Biopharma
―
Tenaya Therapeutics
―
Zura Bio
―
Ownership Overview
―
Insiders
0.63% Mutual Funds
11.65% Other Institutional Investors
87.72% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---